Dopamine agonists: What is the place of the newer compounds in the treatment of Parkinson's disease?

Journal of Neural Transmission, Supplement

Volumn , Issue 55, 1999, Pages 33-45

  Rascol, O ^a,b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; BROMOCRIPTINE; CABERGOLINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; LEVODOPA; LISURIDE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; SEROTONIN RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG ELIMINATION; DRUG HALF LIFE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL TOXICITY; HUMAN; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; DRUG POTENTIATION; REVIEW; TREATMENT OUTCOME;

DOPAMINE AGONISTS; EVIDENCE-BASED MEDICINE; HUMANS; PARKINSON DISEASE; RECEPTORS, DOPAMINE D2; TREATMENT OUTCOME;

EID: 0032589185     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6369-6_4     Document Type: Article

References (62)

1. Adler CH, Scthi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O'Brien CF, for the Ropinirole Study Group (1997) Ropinirole for the treatment of early Parkinson's disease. Neurology 49: 393-399
2. Agid Y (1998) Levodopa: is toxicity a myth. Neurology 50: 858-863
3. Bedard PJ, Di Paolo T, Falardeau P, Boucher R (1986) Chronic treatment with L-dopa, hut not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H] spiperone binding. Brain Res 379: 294-299
4. Bennett JP, Landow ER, Dietrich S, Schuh LA (1994) Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 9: 404-414
5. Bhatt MH, Keenan SP, Fleetham JA, Calne DB (1991) Plcuropulmonary disease associated with dopamine agonist therapy. Ann Neurol 30: 613-616
6. Birkmayer W, Hornykiewicz O (1961) Der L-3,4 dioxyphenylalamin (= dopa)-Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 74: 787-788
7. Blanchet PJ, Konitsiotis S, Chase TN (1997) Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. J Pharmacol Exp Ther 283: 794-799
8. Block G, Liss C, Reines S, Irr J, Nibbelink D and the CR First Study Group (1997) Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. Eur Neurol 37: 23-27
9. Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC (1997) Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 94: 3363-3367
10. Brooks DJ, Abbott RJ, Lees AJ, Martignoni E, Philcox DV, Rascol O, Roos RAC, Sagar HJ (1998) A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol 21: 101-107
11. Calne DB, Teychenne PF, Leigh PN, Baniji AN, Greenacre SK (1974) Treatment of Parkinson's disease with bromocriptine. Lancet 2: 1355-1356
12. Chase TN (1998) The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drug 55: S1-S9
13. Cummings JL (1992) Depression and Parkinson's disease: a review. Am J Psychiatry 149: 443-454
14. Factor SA, Weiner WJ (1993) Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov Disord 3: 257-262
15. Fariello RG (1998) Pharmacodynamic and pharmacokinetic features of Cabergoline. Rationale for use in Parkinson's disease. Drugs 55: S10-S16
16. Felton DL, Felton SY, Fuller RW, Romano TD, Smalstig EB, Wong DT, Clemess JA (1992) Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer-344 rats. Neurobiol Aging 13: 339-351
17. Frans E, Dom R, Demedts M (1992) Pleuropulmonary changes during treatment of Parkinson's disease with a long acting ergot derivative, cabergoline. Eur Respir J 5: 263-265
18. Gomez-Mancilla B, Bedard PJ (1992) Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys. Exp Neurol 117: 185-188
19. Grondin R, Goulet M, Di Paolo T, Bedard PJ (1996) Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates. Brain Res 735: 298-306
20. Grondin R, Bedard PJ, Britton DR, Shiosaki K (1997) Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys. Neurology 49: 421-426
21. Guttman M and the International Pramipexole-Bromocriptine Study Group (1997) Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology 49: 1060-1065
22. Hall ED, Andrus PK, Oostveen JA, Althans JS, Von Voigtlander PF (1996) Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against post ischemic or metamphetamine induced degeneration of nigrostriatal neurons. Brain Res 742: 80-88
23. Hubble JP, Koller WC, Certler NR, Sramek JJ, Friedman J, Goetz C. Ranhosky A, Korts D, Elvin A (1995) Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 18: 338-347
24. Hutton JT, Koller WC, Ahlskog JE, Pahwa R, Hurting HI, Stern MB, Hiner BC, Lieberman A, Pfeiffer RF, Rodnitzky RL, Waters CH, Muenter MD, Adler CH, Morris JL (1996) Multicenter, placebo-controlled trial of cahergolinc taken once daily in the treatment of Parkinson's disease. Neurology 46: 1062-1065
25. Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47 [Suppl 3]: S161-S170
26. Kieburtz K, for the Parkinson Study Group (1997) Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. JAMA 2: 125-130
27. Korczyn A, Brooks D, Brunt E, Poewe W, Rascol O, Stocchi F, on the behalf of the 053 study group (1998) Ropinirole versus bromocriptine in the treatment of Parkinson's disease: a 6 month interim report of a 3 year study. Mov Disord 13: 46-51
28. Kreider M, Knox S, Gardiner D, Wheadon D (1996) A multicenter double-blind study of ropinirole as an adjunct to L-dopa in Parkinson's disease. Neurology 46: 475
29. Larsen JP, Brunt E, Korczyn AD, Nagy Z, Poewe W, Ruggieri S and the 053 Study Group (1998) Ropinirole is effective in long-term treatment of patients with early Parkinson's disease. Neurology 50: 277-278
30. Lieberman A, Imke S, Muenter M, Wheeler K, Ahlskog JE, Matsumoto JY, Maraganore DM, Wright KF, Schoenfelder J (1993) Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. Neurology 43: 1981-1984
31. Luquin MR, Laguna J, Obeso JA (1992) Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann Neurol 31: 551-554
32. Luquin MR, Guillen J, Martinez-Vila E, Laguna J, Martinez-Lage JM (1994) Functional interaction between dopamine D1 and D2 receptors in "MPTP" monkeys. Eur J Pharmacol 253: 215-224
33. Maj J, Rogoz Z, Skuza G, Kolodziejczyk K (1997) Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J Neural Transm 104: 525-533
34. Marsden CD, Parkes JD, Quinn N (1987) Fluctuations of disability in Parkinson's disease: pathophysiological aspects. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth, London, pp 96-122
35. Molho ES, Factor SA, Weiner WJ, Sanchez-Ramos JR, Singer C, Shulman L, Brown D, Sheldon C (1995) The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J Neural Transm 45: 225-230
36. Montastruc JL, Rascol O, Senard JM (1993) Current status of dopamine agonists in Parkinson's disease management. Drugs 46: 384-393
37. Montastruc JL, Rascol O, Senard JM, Rascol A (1994) A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neur Neurosurg Psychiatry 57: 1034-1038
38. Murer MG, Dziewczapolski G, Menalled LB, Garcia MC, Agid Y, Gershanik O, Raisman-Vozari R (1998) Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 43: 561-575
39. Nutt JG (1990) Levodopa-induced dyskinesia. Neurology 40: 340-345
40. Olanow CW (1990) Oxidation reactions in Parkinson's disease. Neurology 40: S32-S39
41. Pearce RKB, Banerji T, Jenner P, Marsden CD (1998) De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 13: 234-241
42. Piercey MF (1998) Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol 21: 141-151
43. Piercey MF, Hoffmann WE, Smith HW, Hyslop DK (1996) Inhibition of dopamine neuron firing by pramipexole, a D3-preferring dopamine agonist: comparaison to other dopamine agonists. Eur J Pharmacol 312: 35-44
44. 18F] dopa PET study. Neurology 50: 330
45. Rascol O (1997) Ropinirole: clinical profile. In: Olanow CW, Obeso JA (cds) Beyond the decade of the brain: Dopamine agonists in early Parkinson's disease. Wells Medical Ltd., Royal Tunbridge Wells, pp 163-176
46. Rascol A, Guiraud B, Montastruc JL, David J, Clanet M (1979) Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry 42: 143-150
47. Rascol O, Lees A, Senard JM, Pirtosek Z, Montastruc JL, Fuell D (1996) Ropinirole in the treatment of levo-dopa induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 19: 234-245
48. Rascol O, Blin O, Descombes S, Soubrouillard C, Fabre N, Viallet F, Thalamas C, Azulay JP, Lafnitzegger K, Fredrick F., Wright S (1997) ABT 431, a selective D1 agonist has efficacy in patients with Parkinson's disease. Neurology 48: 269-270
49. Rascol O, Brooks D, Brunt E, Korezyn A, Poewe W, Stocchi F, on the behalf of the 056 study group (1998) Ropinirole in the treatment of early Parkinson's disease: a 6 month interim report of a 5 year L-dopa controlled study. Mov Disord 13: 39-45
50. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD, Dubini A, Grimaldi NOR, the PKD009 Collaborative Study Group (1997) Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 48: 363-368
51. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Mosso JF, Montastruc JL, Marsden CD, and the Parkinson's Disease S009 Study Group (1998) Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs 55: S23-S30
52. Robertson HA (1992) Dopamine receptor interactions: some implications for the treatment of Parkinson's disease. Trends Neurosci 15: 201-206
53. Ropinirole 043 Study Group (1996) A double-blind comparative study of ropinirole vs. bromocripline in the treatment of Parkinsonian patients not optimally controlled on L-dopa. Mov Disord 11: S188
54. Sethy VH, Wu H, Oostveen JA, Hall ED (1997) Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats. Brain Res 754: 181-186
55. Shannon KM, Bennett JP, Friedman JH, for the Pramipexole Study Group (1997) Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 49: 724-728
56. Szegedi A, Hillert A, Wetzel H, Klieser E, Gaebel W, Benkert O (1997) Pramipexole, a dopamine agonist, in major depression: antidepressant effects and tolerability in an open-label study with multiple doses. Clin Neuropharmacol 20: 536-545
57. Tulloch IF (1997) Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology 49: S58-S62
58. Uitti RJ, Ahlskog JE (1996) Comparative review of dopamine receptor agonist in Parkinson's disease. CNS Drugs 5: 369-388
59. Wheadon D, Wilson-Lynch K, Gardiner D, Kreider M (1996) The efficacy and safety of ropinirole in early Parkinsonian patients not receiving dopaminergic therapy: a multicenter double-blind study. Neurology 46: 159
60. Wise RA, Rompre PP (1989) Brain dopamine and reward. Annu Rev Psychol 40: 191-225
61. Wright CE, Sisson TL, Ichpurani AK, Peters GR (1997) Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 37: 520-525
62. Yoshikawa T, Minamiyama Y, Naito Y, Kondo M (1994) Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 62: 1034-1038